Особенности течения COVID-19 у пациентов с сердечнососудистой патологией
https://doi.org/10.23934/2223-9022-2025-14-4-812-819
Аннотация
Цель. Изучить особенности течения COVID-19 у пациентов с сердечно-сосудистой патологией на основании результатов мировых исследований.
Материал и методы. Поиск статей производили в следующих библиографических базах данных: eLIBRARY.RU, КиберЛенинка, Академия Google, PubMed, Cochrane Central Register of Controlled Trials. Выбраны статьи с рандомизированными клиническими испытаниями с участием взрослых пациентов.
Результаты. В результате поиска обнаружено 146 статей. После оценки их содержания отобрано 65 работ для анализа полного текста статей.
Заключение. Пациенты с сердечно-сосудистыми заболеваниями могут быть подвержены повышенному риску тяжёлого течения COVID-19, при этом сопутствующая патология способна значительно повлиять на прогноз. В свою очередь, коронавирусная инфекция может привести к обострению хронических болезней сердца и сосудов, что подчёркивает значимость своевременной диагностики и применения оптимальных терапевтических подходов.
Об авторах
М. У. Кештова
ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Россия
Кештова Марианна Умаровна, врач-кардиолог, младший научный сотрудник отделения неотложной клинической кардиологии с методами неинвазивной функциональной диагностики
129090, Москва, Большая Сухаревская пл., д. 3
Г. А. Газарян
ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Россия
Газарян Георгий Арташесович, профессор, доктор медицинских наук, заведующий научным отделением неотложной клинической кардиологии с методами неинвазивной функциональной диагностики
129090, Москва, Большая Сухаревская пл., д. 3
С. С. Петриков
ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Россия
Петриков Сергей Сергеевич, академик РАН, доктор медицинских наук, директор
129090, Москва, Большая Сухаревская пл., д. 3
Список литературы
1. Kite TA, Pallikadavath S, Gale CP, Curzen N, Ladwiniec A. The Direct and Indirect Effects of COVID-19 on Acute Coronary Syndromes. Heart Fail Clin. 2023;19(2):185–196. PMID: 36863810 https://doi.org/10.1016/j.hfc.2022.08.002
2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. PMID: 32142651 https://doi.org/10.1016/j.cell.2020.02.052
3. Nguyen L, McCord KA, Bui DT, Bouwman KM, Kitova EN, Elaish M, et al. Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. Nat Chem Biol. 2022;18(1):81–90. PMID: 34754101 https://doi.org/10.1038/s41589-021-00924-1
4. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–292.e6. PMID: 32155444 https://doi.org/10.1016/j.cell.2020.02.058
5. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. PMID: 14647384 https://doi.org/10.1038/nature02145
6. Azevedo RB, Botelho BG, Hollanda JVG, Ferreira LVL, Junqueira de Andrade LZ, Oei SSML, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4–11. PMID: 32719447 https://doi.org/10.1038/s41371-020-0387-4
7. Ng SM, Pan J, Mouyis K, Kondapally Seshasai SR, Kapil V, Rice KM, et al. Quantifying the excess risk of adverse COVID-19 outcomes in unvaccinated individuals with diabetes mellitus, hypertension, ischaemic heart disease or myocardial injury: a meta-analysis. Front Cardiovasc Med. 2022;26(9):871151. PMID: 35557537 https://doi.org/10.3389/fcvm.2022.871151 eCollection 2022.
8. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. PMID: 32408793 https://doi.org/10.1177/1470320320926899
9. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elsayed H, Dalvi B, Malakan Rad E. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. Egypt Heart J. 2020;72(1):41. PMID: 32661796 https://doi.org/10.1186/s43044-020-00075-z
10. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium; et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. PMID: 32320003 https://doi.org/10.1001/jama.2020.6775
11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. PMID: 31986264 https://doi.org/10.1016/S0140-6736(20)30183-5
12. Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В., Кравчук Ю.А., Педь В.И., и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Кардиоваскулярная терапия и профилактика. 2020;19(4):135–172. https://doi.org/10.15829/1728-8800-2020-2630
13. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239–1242. PMID: 32091533 https://doi.org/10.1001/jama.2020.2648
14. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. PMID: 32161990 https://doi.org/10.1007/s00392-020-01626-9
15. Бубнова М.Г., Аронов Д.М. COVID-19 и сердечно-сосудистые заболевания: от эпидемиологии до реабилитации. Пульмонология. 2020;30(5):688–699. https://doi.org/10.18093/0869-0189-2020-30-5-688-699
16. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. PMID: 32031570 https://doi.org/10.1001/jama.2020.1585
17. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. PMID: 32253449 https://doi.org/10.1007/s00134-020-05991-x
18. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide analysis. Eur Respir J. 2020;55(5):2000547. PMID: 32217650 https://doi.org/10.1183/13993003.00547-2020
19. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–1776. PMID: 32203977 https://doi.org/10.1001/jama.2020.4683
20. Prabhakaran D, Singh K, Kondal D, Raspail L, Mohan B, Kato T, et al.; WHF COVID-19 Study Collaborators. Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. Glob Heart. 2022;17(1):40. PMID: 35837356 https://doi.org/10.5334/gh.1128 Erratum in: Glob Heart. 2022;17(1):79. https://doi.org/10.5334/gh.1167
21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. PMID: 32171076 https://doi.org/10.1016/S0140-6736(20)30566-3
22. Yanai H. A significance of high prevalence of diabetes and hypertension in severe COVID-19 patients. J Clin Med Res. 2020;12(6):389–392. PMID: 32587655 https://doi.org/10.14740/jocmr4218
23. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049–6057. PMID: 32267833 https://doi.org/10.18632/aging.103000
24. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618–625. PMID: 19453650 https://doi.org/10.1111/j.1365-2362.2009.02153.x
25. Фисун А.Я., Черкашин Д.В., Тыренко В.В., Жданов К.В., Козлов К.В. Роль ренинангиотензин-альдостероновой системы во взаимодействии с коронавирусом SARS-CoV-2 и в развитии стратегий профилактики и лечения новой коронавирусной инфекции (COVID-19). Артериальная гипертензия. 2020;26(3):248–262. https://doi.org/10.18705/1607-419X-2020-26-3-248-262
26. Zhu H, Rhee JW, Cheng P, Waliany S, Chang A, Witteles RM, et al. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep. 2020;22(5):32. PMID: 32318865 https://doi.org/10.1007/s11886-020-01292-3 Erratum in: Curr Cardiol Rep. 2020;22(5):36. https://doi.org/10.1007/s11886-020-01302-4
27. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitisin COVID-19. Lancet. 2020;395(10234):1417–1418. PMID: 32325026 https://doi.org/10.1016/S0140-6736(20)30937-5
28. Ghasemzadeh N, Kim N, Amlani S, Madan M, Shavadia JS, Chong AY, et al. A Review of ST-Elevation Myocardial Infarction in Patients with COVID-19. Heart Fail Clin. 2023;19(2):197–204. PMID: 36863811 https://doi.org/10.1016/j.hfc.2022.08.007
29. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect. 2020;80(6):607–613. PMID: 32283152 https://doi.org/10.1016/j.jinf.2020.03.037
30. Smeeth L, Thomas SL, Hall A, Hubbard RB, Farrington CP, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611–2618. PMID: 15602021 https://doi.org/10.1056/NEJMoa041747
31. Ackermann M, Verleden SE, Kuehnel M. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128. PMID: 32437596 https://doi.org/10.1056/NEJMoa2015432
32. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, et al. Pulmonary Arterial Thrombosis in COVID-19 with Fatal Outcome: Results from a Prospective, Single-Center, Clinicopathologic Case Series. Ann Intern Med. 2020;173(5):350–361. PMID: 32422076 https://doi.org/10.7326/M20–2566
33. Ornelas-Ricardo D, Jaloma-Cruz AR. Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy. Tohoku J Exp Med. 2020;251(4):327–336. PMID: 32788506 https://doi.org/10.1620/tjem.251.327
34. Dodig S, Čepelak I, Čepelak Dodig D, Laškaj R. SARS-CoV-2 – a new challenge for laboratory medicine. Biochem Med (Zagreb). 2020;30(3):030503. PMID: 32774121 https://doi.org/10.11613/BM.2020.030503
35. Laguna-Goya R, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramirez-Fernandez A, Naranjo L, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(4):799–807.e9. PMID: 32710975 https://doi.org/10.1016/j.jaci.2020.07.009
36. Vinciguerra M, Romiti S, Fattouch K, De Bellis A, Greco E. Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm. J Clin Med. 2020;9(7):2095. PMID: 32635302 https://doi.org/10.3390/jcm9072095
37. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. PMID: 32442528 https://doi.org/10.1016/S0140–6736(20)31189–2
38. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–1026. PMID: 32338827 https://doi.org/10.1111/jth.14810
39. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al.; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020;75(23):2950–2973. PMID: 32311448 https://doi.org/10.1016/j.jacc.2020.04.031
40. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440.PMID: 32407672 https://doi.org/10.1016/S2352-3026(20)30145-9
41. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolys. 2020;50(1):54–67. PMID: 32415579 https://doi.org/10.1007/s11239–020-02134–3
42. Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, et al. Dying with SARS-CoV-2 infection— an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Intern J Legal Med. 2020;134(4):1275–1284. PMID: 32500199 https://doi.org/10.1007/s00414–020-02317-w
43. Zhao J, Xie Y, Meng Z, Liu C, Wu Y, Zhao F, et al. COVID-19 and cardiovascular complications: updates of emergency medicine. Emerg Crit Care Med. 2023;3(3):104–114. PMID: 38314258 https://doi.org/10.1097/ec9.0000000000000095
44. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. PMID: 32219356 https://doi.org/10.1001/jamacardio.2020.1017
45. Thygesen K, Alpert JS, Jaffe AS, Chairman BR, Bax JJ, Morrow DA, et al.; Executive group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Univers Défin Myocard Infarct. Glob Heart. 2018;13(4):305–338. PMID: 30154043 https://doi.org/10.1016/j.gheart.2018.08.004
46. Ларина В.Н., Головко М.Г., Ларин В.Г. Влияние коронавирусной инфекции (COVID-19) на сердечно-сосудистую систему. Вестник РГМУ. 2020;(2):5–13. https://doi.org/10.24075/brsmu.2020.020
47. Шляхто Е.В., Конради А.О., Арутюнов А.Г., Баутипн А.Е., Бойцов С. А. и др. Руководство по диагностике и лечению болезней системы кровообращения (БСК) в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):129–148. https://doi.org/10.15829/1560-4071-2020-3-3801
48. Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol. 2020;5(7):751–753. PMID: 32219362 https://doi.org/10.1001/jamacardio.2020.1105
49. ESC European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Available at: https://www.acilcalisanlari.com/wp-content/uploads/2020/05/ESC-Guidance-COVID-19-Pandemic.pdf [Accessed March 06, 2025].
50. Alvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, et al. Prognostic Impact of Prior Heart Failure in Patients Hospitalized with COVID-19. J Am Coll Cardiol. 2020;76(20):2334–2348. PMID: 33129663 https://doi.org/10.1016/j.jacc.2020.09.549
51. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819–824. PMID: 32219357 https://doi.org/10.1001/jamacardio.2020.1096
52. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507–513. PMID: 32007143 https://doi.org/10.1016/S0140-6736(20)30211-7
53. König S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A; Helios Hospitals, Germany. In-hospital care in acute heart failure during the COVID-19 pandemic: Insights from the German-wide Helios hospital network. Eur J Heart Fail. 2020;22(12):2190–2201. PMID: 33135851 https://doi.org/10.1002/ejhf.2044
54. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41(19):1821–1829. PMID: 32383763 https://doi.org/10.1093/eurheartj/ehaa388
55. Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail. 2020;22(12):2238–2247. PMID: 33179839 https://doi.org/10.1002/ejhf.2052
56. Ермохина Л.В., Берикашвили Л.Б., Ядгаров М.Я., Чаус Н.И., Баева А. А., Мельникова Н.С., и др. Оценка влияния сердечно-сосудистых заболеваний и их медикаментозной терапии на летальность пациентов с COVID-19, получавших лечение в отделении реанимации. Анестезиология и реаниматология. 2022;(1):36–43. https://doi.org/10.17116/anaesthesiology202201136
57. Giugni FR, Duarte-Neto AN, da Silva LFF, Monteiro RAA, Mauad T, Saldiva PHN, et al. Younger age is associated with cardiovascular pathological phenotype of severe COVID-19 at autopsy. Front Med (Lausanne). 2024;10:1327415. PMID: 38259848 https://doi.org/10.3389/fmed.2023.1327415
58. Cannatà A, Bromage DI, Rind IA, Gregorio C, Bannister C, Albarjas M, et al. Temporal trends in decompensated heart failure and outcomes during COVID-19: A multisite report from heart failure referral centres in London. Eur J Heart Fail. 2020;22(12):2219–2224. PMID: 32809274 https://doi.org/10.1002/ejhf.1986
59. Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116(10):1688–1699. PMID: 32293003 https://doi.org/10.1093/cvr/cvaa097. Erratum in: Cardiovasc Res. 2021;117(11):2394. https://doi.org/10.1093/cvr/cvab224
60. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Rev Cardiol. 2020;17(5):259–260. PMID: 32139904 https://doi.org/10.1038/s41569-020-0360-5
61. Vinciguerra M, Romiti S, Sangiorgi GM, Rose D, Miraldi F, Greco E. SARS-CoV-2 and Atherosclerosis: Should COVID-19 Be Recognized as a New Predisposing Cardiovascular Risk Factor? J Cardiovasc Dev Dis. 2021;8(10):130. PMID: 34677199 https://doi.org/10.3390/jcdd8100130
62. Hessami A, Shamshirian A, Heydari K, Pourali F, Alizadeh-Navaei R, Moosazadeh M, et al. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Am J Emerg Med. 2021;46:382–391. PMID: 33268238 https://doi.org/10.1016/j.ajem.2020.10.022
63. Ma C, Cong Y, Zhang H. COVID-19 and the Digestive System. Am J Gastroenterol. 2020;115(7):1003–1006. PMID: 32618648 https://doi.org/10.14309/ajg.0000000000000691
64. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю. А., Гарганеева А.А., и др. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8–158. https://doi.org/10.18087/cardio.2475
65. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection. J Am Coll Cardiol. 2020;76(5):533–546. PMID: 32517963 https://doi.org/10.1016/j.jacc.2020.06.007
Рецензия
Для цитирования:
Кештова М.У., Газарян Г.А., Петриков С.С. Особенности течения COVID-19 у пациентов с сердечнососудистой патологией. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2025;14(4):812-819. https://doi.org/10.23934/2223-9022-2025-14-4-812-819
For citation:
Keshtova M.U., Gazaryan G.A., Petrikov S.S. Features of COVID-19 in Patients with Cardiovascular Pathology. Russian Sklifosovsky Journal "Emergency Medical Care". 2025;14(4):812-819. (In Russ.) https://doi.org/10.23934/2223-9022-2025-14-4-812-819
Просмотров:
10
JATS XML
Послать статью по эл. почте 